FDA Would Lose Direct Access To User Fees Under House Bill
This article was originally published in The Tan Sheet
A bill pending in the House Energy & Commerce Committee would place all fees collected from companies regulated by FDA in a general Treasury fund
You may also be interested in...
A new safety center proposed in Sen. Charles Grassley's "FDA Safety Act" (FDASA) would have broad postmarket authority over some over-the-counter drugs, as well as prescription pharmaceuticals and biologics
FDA advisory committee votes in favor of continued availability of COX-2s in the U.S. are "tainted" due to conflicts of interest among panelists, according to a Feb. 25 letter from Senate Finance Committee Chairman Chuck Grassley (R-Iowa)
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC